PD-L1 Expression and CD8 + T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer

European Urology Focus

Volumn 5, Issue 2, 2019, Pages 192-196

  Petitprez, Florent ^a,b,c,d   Fossati, Nicola ^e   Vano, Yann ^a,b,c,f   Freschi, Massimo ^e   Becht, Etienne ^a,b,c   Lucianò, Roberta ^e   Calderaro, Julien ^a,b,c   Guédet, Tiffany ^a,b,c   Lacroix, Laetitia ^a,b,c   Rancoita, Paola M V ^g   Montorsi, Francesco ^e,g   Fridman, Wolf Herman ^a,b,c   Sautès Fridman, Catherine ^a,b,c   Briganti, Alberto ^e,g   Doglioni, Claudio ^e,g   Bellone, Matteo ^e  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d Cartes d'Identité des Tumeurs Program   (France)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

B lymphocytes; Biomarker; Immune checkpoint; Lymph node metastasis; PD L1; Progression; Prostate cancer; Radical prostatectomy; Recurrence; T lymphocytes

Indexed keywords

CD20 ANTIGEN; CD8 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; ANTIANDROGEN; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ADJUVANT; TUMOR MARKER;

ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DENSITY; COHORT ANALYSIS; DISTANT METASTASIS; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; LYMPH NODE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; PROSTATECTOMY; TUMOR RECURRENCE;

ADJUVANTS, IMMUNOLOGIC; ANDROGEN ANTAGONISTS; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; CD8-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 85021143628     PISSN: None     EISSN: 24054569     Source Type: Journal    
DOI: 10.1016/j.euf.2017.05.013     Document Type: Article

References (12)

1. Abdollah, F., Suardi, N., Gallina, A., et al. Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center. Ann Oncol 24 (2013), 1459–1466.
2. Mottet, N., Bellmunt, J., Bolla, M., et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol, 2016.
3. Touijer, K.A., Mazzola, C.R., Sjoberg, D.D., Scardino, P.T., Eastham, J.A., Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol 65 (2014), 20–25.
4. Briganti, A., Karnes, J.R., Da Pozzo, L.F., et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 55 (2009), 261–270.
5. Schumacher, M.C., Burkhard, F.C., Thalmann, G.N., Fleischmann, A., Studer, U.E., Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 54 (2008), 344–352.
6. Becht, E., Giraldo, N.A., Germain, C., et al. Immune contexture, immunoscore, and malignant cell molecular subgroups for prognostic and theranostic classifications of cancers. Adv Immunol 130 (2016), 95–190.
7. Woo, J.R., Liss, M.A., Muldong, M.T., et al. Tumor infiltrating B-cells are increased in prostate cancer tissue. J Transl Med, 12, 2014, 30.
8. Leclerc, B.G., Charlebois, R., Chouinard, G., et al. CD73 expression is an independent prognostic factor in prostate cancer. Clin Cancer Res 22 (2016), 158–166.
9. Wu, P., Wu, D., Li, L., Chai, Y., Huang, J., PD-L1 and survival in solid tumors: a meta-analysis. PLoS One, 10, 2015, e0131403.
10. Gevensleben, H., Dietrich, D., Golletz, C., et al. The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer. Clin Cancer Res 22 (2016), 1969–1977.
11. Sharma, P., Hu-Lieskovan, S., Wargo, J.A., Ribas, A., Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168 (2017), 707–723.
12. Beer, T.M., Kwon, E.D., Drake, C.G., et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol 35 (2017), 40–47.